Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Commits To PCSK9 Phase III, Tightening First-To-Market Race

Jul 30 2012

• By Jessica Merrill

Related Content

In One Day, Change At Biotechs: Leiden To Replace Emmens At Vertex And At Amgen, Bradway Will Become CEO

Dec 15 2011

Regeneron/Sanofi’s PSCK9 Inhibitor Might Need Two-Week Dosing Schedule

May 30 2012

Related Companies

Amgen, Inc.

Regeneron Pharmaceuticals, Inc.

UCB S.A.

Takeda Pharmaceutical Co. Ltd.

Pfizer Inc.

Additional Topics

Business Strategies Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window